Penn researchers identify natural tumor suppressor

September 10, 2008

Better understanding of early-stage cancer crucial to finding new therapies

PHILADELPHIA - Researchers from the University of Pennsylvania School of Medicine have identified a key step in the formation - and suppression - of esophageal cancers and perhaps carcinomas of the breast, head, and neck. By studying human tissue samples, they found that Fbx4, a naturally occurring enzyme, plays a key role in stopping production of another protein called Cyclin D1, which is thought to contribute to the early stages of cancer development.

When mutations block production of Fbx4, Cyclin D1 is not broken down, and subsequently contributes to cancer's advance. Fbx4 acts like a bouncer, stopping trouble before it starts by breaking down Cyclin D1 before it can affect the body.

"Cyclin D1 was identified nearly 20 years ago and after that, it became apparent that it was overexpressed in a high percentage of tumors," says J. Alan Diehl, PhD, Associate Professor of Cancer Biology at the University of Pennsylvania's Abramson Family Cancer Research Institute. "But its expression didn't correlate to mutations within Cyclin D1, so we were looking for a protein that regulates accumulation. That's Fbx4."

For this study, researchers screened 116 esophageal tumors and found 16 mutations. Their findings were published in a recent issue of Cancer Cell.

The actual mutations researchers found are located within a highly conserved region of Fbx4 that functions like an on switch. Mutations within that switch region inhibit activation of Fbx4, which means it can't trigger destruction of Cyclin D1.

The results are important in that they show how Cyclin D1 becomes so prevalent in tumors. Before, it was thought that Cyclin D1 was present because of a mutation somewhere in the DNA of a cell. Instead, this study shows that Cyclin D1 naturally occurs, but our bodies have created a natural defense mechanism that breaks it down before cancer develops.

"When Fbx4 is inactivated, it permits the accumulation of its target, CyclinD1," says Diehl.

While it remains important to define the cause of the initial mutations, this study provides researchers with a better understanding of the early stages of cancer which is crucial to finding a way to reverse the process.

University of Pennsylvania School of Medicine

---

---

	Tumor Suppressor Genes: Volume 2: Regulation, Function, and Medicinal Applications (Methods in Molecular Biology) by Wafik S. El-Deiry (Editor) The second volume of Tumor Suppressor Genes explores the cell biology and biochemical function of the tumor suppressor genes, as well as its physiological role in vivo. The authors detail the physical methods (NMR, microarray approaches, pot-translational structure analysis, analysis of regulation at the gene expression and protein signaling levels)used to understand the function of tumor suppressor genes. In vivo approaches discussed include studies in yeast, Drosophilia, mice, and human tumors. For both volumes: Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or...
	Tumor Suppressor Genes by Katherine R. Polinsky (Editor) A tumour suppressor gene is a gene that reduces the probability that a cell in a multicellular organism will turn into a tumor cell. A mutation or deletion of such a gene will increase the probability of the formation of a tumor. Unlike oncogenes, tumor suppressor genes generally follow the 'two-hit hypothesis', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is due to the fact that if only one allele for the gene is damaged, the second can still produce the correct protein. However, there are cases where mutations in only one allele will cause an effect. A notable example is the gene that codes for p53. Tumor suppressor genes, or more precisely, the proteins for which they code, either have a dampening or repressive...
	Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development) by David E. Fisher (Editor) David Fisher, MD, PhD, and an authoritative panel of academic, cutting-edge researchers review and summarize the current state of the field. Describing the broad roles of tumor suppressors from a perspective based in molecular biology and genetics, the authors detail the major suppressors and the pathways they regulate, including cell cycle progression, stress responses, apoptosis, and responses to DNA damage. Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.
	Enzymes Involved in Heparan Sulfate Chain Elongation: Function of a Novel Family of Tumor Suppressors (Comprehensive Summaries of Uppsala Dissertations) by Thomas Lind (Author)
	New Developments in Metastasis Suppressor Research by Paul Jackson (Editor) The spread of cancer cells from their organ of origin to distant tissues is called metastasis. Cancer metastasis is the main cause of death from cancer, and in many cases is difficult to detect or treat. The process by which tumour cells become metastatic is complex and involves many stages, including detachment of cells from the main tumour mass, degradation of the surrounding extra-cellular matrix, invasion into nearby blood vessels, travel and survival through the circulatory system, attachment to a vessel wall, extra-vasation, degradation of the extra-cellular matrix into a distant tissue/organ, and the development of a novel blood supply. In order to accomplish this process, the cells acquire characteristics which are important for each stage.Recently, a class of genes known as...
	The p53 Tumor Suppressor Pathway and Cancer (Protein Reviews, Vol. 2) by Gerard P. Zambetti (Editor) The p53 tumor suppressor gene is mutated in approximately half of all human malignancies, including colon, lung, and breast cancers. It is well recognized that these mutations directly inactivate p53 tumor suppressor function. Furthermore, the p53 protein operates within a pathway and this pathway, including the mutations in p53, is likely inactivated by nearly every human tumor. In support of this hypothesis, 100% of mice that have been engineered such that they do not express p53 protein (knockout animals), develop highly malignant tumors by only 3-6 months of age. The importance of p53 in preventing human cancer is also evident by families in which a mutated p53 gene is inherited from a parent. Individuals who carry an inherited germline p53 mutation are associated with Li-Fraumeni...
	Oncogenes and Tumor Suppressor Genes in Human Malignancies (Cancer Treatment and Research) by C.C. Benz (Editor), E.T. Liu (Editor) This volume begins by reviewing selected malignancies in which the search for clinically relevant oncogenes has led to more focused studies on gain-of-function and loss-of-function genetic abnormalities, as well as autocrine and paracrine growth factor loops known to regulate tumor physiology and malignant cell behavior. Many of these genetic and functional abnormalities are shared by several different tumor types and are not uniformly present in all tumors of the same type. This observation brings up molecular questions about the tissue-specific determinants that underlie individual cancers and also gives added impetus to the suggestion that molecular abnormalities (referred to as tumor markers) be included among the histopathologic features used for clinical diagnosis and...
	Tumor Suppressor Genes (Immunology Series) by George Klein (Editor)
	Tumor Suppressor Genes: Volume 1: Pathways and Isolation Strategies (Methods in Molecular Biology) by Wafik S. El-Deiry (Editor) Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or sporadic cancers. They also provide a detailed guide to using powerful molecular genetic, cytogenetic, proteomic, and cell biological strategies to discover and isolate novel tumor suppressor genes and their targets. For both volumes: Leading physician scientists and academic researchers review all the known tumor suppressor genes, explain how they work, and describe how they were discovered and isolated. In many cases, the authors discuss specific genes that are frequently involved in hereditary or sporadic cancers. They...
	Tumor Suppressors: Involvement in Human Diseases, Viral Protein Interactions and Growth Regulation (Molecular Biology Intelligence Unit) by John W. Ludlow (Author), Gary R. Skuse (Author)